Seoul: South Korean biopharmaceutical firm Celltrion Inc. announced on Thursday its decision to allocate approximately 100 billion won (US$71.5 million) for the repurchase of its shares, marking the fifth buyback initiative this year aimed at bolstering shareholder value. The repurchase will involve a total of 583,431 shares and is set to commence on Friday.According to Yonhap News Agency, this marks the fifth share buyback by Celltrion in 2023, following similar actions in March, April, June, and October. With this latest move, the total value of Celltrion's share buybacks for the year is projected to reach 430 billion won. Despite achieving record sales of 881.9 billion won in the third quarter and witnessing the growth of its flagship products in the global market, the company believes its corporate value remains undervalued.Earlier this year, Celltrion repurchased shares worth 1.27 trillion won and proceeded to cancel 700 billion won worth of them. The company is also contemplating additional share pu rchases and cancellations to stabilize in response to recent market volatility in the domestic financial market. As of 10:50 a.m., Celltrion's shares were trading at 176,800 won, reflecting a 3.15 percent increase from the previous session's close.
- October 12, 2026
